10-Q · latest 10
What Merck's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 8 signals
Merck completes ~$6.8B acquisition of Terns, funded by $6B in new debt.
$6.8B
Cash consideration for the acquisition of Terns
Terns Pharmaceuticals, Inc.Cidara Therapeutics, Inc.
Merck spent $15.8 billion on investing activities in the first half of 2026, a massive increase from $2.3 billion in the prior year, primarily for acquisitions.
$15.8B
Cash used in investing activities in the first six months of 2026
Merck raised $12B+ in financing via debt and credit to fund $6.8B Terns acquisition.
The company secured a $6.0B term loan and issued $6.0B in senior notes to fund the $6.8B acquisition of Terns.
$6.8B
Cash consideration for the acquisition of Terns
With the emergency use authorization for its COVID-19 drug Lagevrio ending and no new drug approval expected before the deadline, Merck faces the operational challenge of winding down the product in the U.S.
Merck's R&D strategy is heavily reliant on complex collaborations for its late-stage pipeline, including oncology and vaccines.
Gilead Sciences, Inc.Daiichi SankyoModerna Inc.Eisai Co., Ltd.
Emergency Use Authorization for COVID-19 drug Lagevrio will terminate in June 2027.
The US government has announced the termination of the Emergency Use Authorization (EUA) for Lagevrio, a key COVID-19 treatment, effective June 29, 2027.
Merck & Gilead discontinue Phase 3 trial, highlighting clinical data analysis challenges
The failure of a key late-stage oncology trial with Gilead, based on an external data monitoring committee's recommendation, exposes potential weaknesses in R&D data analysis.
WuXi VaccinesGilead Sciences, Inc.Eisai Co., Ltd.AstraZeneca
- SEC EDGAR
10-Q
Filed · 12 signals
Merck to acquire Terns for ~$6.7B, securing $6.0B in financing for the deal.
$6.7B
cash consideration for the acquisition of Terns
Terns Pharmaceuticals Inc.
Merck completes acquisition of Cidara, driving a significant increase in investing cash outflow.
The completed acquisition of Cidara was a primary driver for a multi-billion dollar increase in cash used for investing activities in Q1 2026.
$8.7B
Increase in cash used in investing activities ($10.2B vs $1.5B YoY) primarily due to Cidara acquisition
Cidara Therapeutics Inc.
Merck securing $6.0B term loan to fund $6.7B acquisition of Terns
The company is taking on significant new debt to finance a major acquisition, indicating a strategic focus on growth through M&A.
$6B
Delayed draw term loan facility to fund acquisition
Showing 10 of 20 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Merck earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Announced massive $70B investment in US manufacturing and R&DA multi-year plan to expand domestic manufacturing and R&D signals significant capital expenditure and a need for suppliers, technology, and services to support this large-scale growth. | |
| Announced massive $70B+ investment in US manufacturing and R&DThe company is making a multi-decade, $70 billion investment to expand domestic manufacturing and R&D, signaling significant capital expenditure and budget for new facilities, equipment, and research infrastructure. | |
| Facing significant pricing pressure from IRA and generic competitionThe company anticipates revenue headwinds from IRA price setting on its JANUVIA franchise and loss of exclusivity for key drugs like DIFICID and BRIDION. This pressure could drive initiatives focused on operational efficiency and cost reduction to protect margins. | |
| Executing a $5 billion share repurchase program for the full yearA $5B share buyback program underscores the company's strong financial position and cash generation, indicating they have sufficient capital to fund both shareholder returns and strategic operational investments. | |
| Strategically differentiating TROP2 ADC from competitors in clinical trialsThe Head of Research Labs highlighted a deliberate strategy to differentiate their TROP2 ADC, sac-TMT, by pursuing 10 of its 15 Phase III studies in indications where competing TROP2s have not gone. This signals an aggressive, well-funded clinical strategy to outmaneuver rivals and capture new market segments. | |
| Launching subcutaneous KEYTRUDA to improve healthcare system efficiencyThe launch of KEYTRUDA QLEX (subcutaneous) is a strategic move to increase efficiency and access in healthcare systems by reducing administration time. This shift creates needs for new patient support programs, logistics, and technologies supporting care outside traditional infusion centers. |
Signal API · MCP
Track Merck with the Signal API
One POST /v1/companies/enrich call with merck.com returns Merck 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"merck.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Merck 10-Q
When did Merck file its latest 10-Q?
What did Merck disclose in its latest 10-Q?
What did Merck say on its recent earnings calls?
Where can I read Merck's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .